Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) has submitted a provisional patent application for its photothermal light device aimed at photothermal therapy. Developed in collaboration with Minnetronix Medical, the device utilizes an 860 nanometer wavelength infrared laser and biocompatible gold nanorods to convert light energy into heat. The company is conducting pre-clinical efficacy studies for its cancer treatment at Dalhousie University. Insights from discussions with U.S. surgeons and payer representatives, along with FDA feedback, guide the development and validation path for Sona's therapy. CEO David Regan highlighted the importance of recent feedback in refining research pathways. Additionally, Dr. Carman Giacomantonio, a surgical oncologist and professor, has joined Sona's Advisory Board, overseeing the current pre-clinical study at Dalhousie University.